Celecoxib and heterotopic bone formation after total hip arthroplasty.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 23927909.
- Also identified by DOI 10.1016/j.arth.2013.06.039.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We assessed the effectiveness of celecoxib in the prevention of heterotopic ossification (HO) following primary total hip replacement (THR). We studied 170 consecutive THRs. Sixty-three patients received celecoxib after surgery (200mg twice/daily) for 28 days and 84 did not. HO was more common in non-celecoxib patients than in the celecoxib-group at 3, 6, and 12 months (P =0.005, 0.004 and 0.01, respectively). At 1 year, fewer celecoxib recipients had Brooker classes II or III. None of the celecoxib patients developed HO Brooker class IV, while 2% in the non-celecoxib group did. No patient discontinued treatment or had revision for aseptic loosening. A short course of celecoxib for pain aids in the prevention of HO after primary THR, and could be a useful and safe option that does not interfere with anticoagulation.
Medical subject headings
- Anti-Inflammatory Agents, Non-Steroidal
- Arthroplasty, Replacement, Hip
- Hip Joint
- Joint Diseases
- Ossification, Heterotopic
- Pyrazoles
- Sulfonamides
Anatomy
- hip